TRPA1 channel agonists can treat obesity and other related diseases, such as type 2 diabetes, by regulating the secretion of insulin, providing a new avenue for study on the treatment of diabetes (Liu et al., 2019; Sahin et al., 2019). Here, INS is linked to type 2 diabetes mellitus.